Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31005200 | 0.79 | MMP12 (0.47) | GRM2BACE1HRH4 | |
| SCHEMBL18341299 | 0.79 | MMP12 (0.47) | GRM2BACE1HRH4 | |
| SCHEMBL7894744 | 0.79 | GRM2 (0.43) | GRM2LCKALDH1A1NPC1RAB9A | |
| SCHEMBL1656828 | 0.79 | GRM2 (0.42) | SMN1; SMN2GRM2LCKALDH1A1BACE1 | |
| SCHEMBL15228958 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2GRM2ALDH1A1ENPP3ENPP1 | |
| SCHEMBL26107139 | 0.77 | GRM2 (0.57) | SMN1; SMN2GRM2ALDH1A1 | |
| SCHEMBL30685057 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM2LCKHSD11B1ALDH1A1 | |
| SCHEMBL12970516 | 0.77 | GRM2 (0.47) | SMN1; SMN2GRM2ALDH1A1NPC1RAB9A | |
| SCHEMBL25168477 | 0.75 | GRM2 (0.40) | SMN1; SMN2GRM2LCKALDH1A1BACE1 | |
| SCHEMBL31220150 | 0.75 | GRM2 (0.40) | SMN1; SMN2GRM2LCKALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| US-8772504-B2 | Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772504-B2 | Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010094647-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SMN1; SMN2 2060/4885GRM2 870/4885LCK 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.